Global pharma major Lupin Limited (Lupin) has recently informed exchanges that the company has launched the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. As the first generic to be approved and launched, the company is entitled to 180 days of competitive generic therapy (CGT) exclusivity.
In the exchange filing, the company also shared, “Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte® Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroidresponsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte® had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024).”
